Liquidia’s (LQDA) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Liquidia (NASDAQ:LQDA) in a report released on Thursday morning,Benzinga reports. Needham & Company LLC currently has a $19.00 price target on the stock.

A number of other analysts have also weighed in on LQDA. Scotiabank initiated coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. Wells Fargo & Company initiated coverage on shares of Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Liquidia currently has an average rating of “Buy” and a consensus price target of $25.38.

Liquidia Price Performance

Shares of Liquidia stock opened at $12.19 on Thursday. The firm has a market cap of $1.03 billion, a P/E ratio of -7.48 and a beta of 0.23. The firm has a 50 day simple moving average of $11.15 and a 200 day simple moving average of $11.04. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99.

Insider Transactions at Liquidia

In other news, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the transaction, the insider now directly owns 207,383 shares in the company, valued at $2,304,025.13. The trade was a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the transaction, the general counsel now owns 486,048 shares in the company, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,007 shares of company stock worth $245,780 in the last ninety days. Insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Whitefort Capital Management LP raised its holdings in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after acquiring an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after acquiring an additional 230,820 shares during the period. JPMorgan Chase & Co. raised its holdings in Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after acquiring an additional 210,753 shares during the period. Bank of New York Mellon Corp raised its holdings in Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock valued at $2,496,000 after acquiring an additional 32,076 shares during the period. Finally, HighVista Strategies LLC raised its holdings in Liquidia by 48.6% in the 3rd quarter. HighVista Strategies LLC now owns 180,947 shares of the company’s stock valued at $1,809,000 after acquiring an additional 59,193 shares during the period. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).